Combined with the results that upregulated fucosylation level was required for cancer growth and metastasis 49, 50, our results highlighted the therapeutic potential of targeting TSTA3 and fucosylation inhibitor to treat metastatic ESCC. This evidence concerns the gene GFUS and esophageal squamous cell carcinoma.